Table 3 Summary of PK parameters of gliclazide and optimized formulation, SGNCF1 on type II diabetic rats after single oral dose administration.

From: Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model

PK parameters

Pure gliclazide

SGNCF1

Cmax (ng/ml)

382.182 ± 15.140

1232.19 ± 124.39

Tmax (h)

2 ± 1

2 ± 1

t half (h)

9.75 ± 0.55

29.56 ± 3.53

Cl (ml/h)

1503.87 ± 0.036

265.539 ± 0.005

Vss (ml)

22586.6 ± 0.12

11023.7 ± 0.10

AUC total (µg/ml × h)

5.3485 ± 0.51

30.291 ± 1.42

AUMC total (µg/ml) × (h)2

80.32 ± 5.104

1257.52 ± 128.578

MRT (h)

15.019 ± 2.740

41.51 ± 1.593

β (1/h)

−0.071 ± 0.003

−0.023 ± 0.0069

  1. SD: standard deviation; (n = 6).
Back to article page